SupplementsProactive HealthInfant HealthLC40 InfantHereditum® LC40® Infant Research Studies

Hereditum® LC40® Infant

LC40® Infant (Limosilactobacillus fermentum CECT5716) is the first probiotic strain obtained from the breast milk of healthy mothers, isolated and characterised for the unique health benefits provided for babies and new moms. Clinical research suggests it’s safe and effective at supporting infant´s immune and digestive health.

Human Milk Probiotic Lactobacillus fermentum CECT5716 Reduces the Incidence of Gastrointestinal and Upper Respiratory Tract Infections in Infants LC40®. A RCT, double blinded, controlled, and multicenter study.
A randomised doble-blind clinical study in 188 healthy exclusively formula-fed infants was performed from 1 to 6 months old. The infants who took the formula supplemented with GOS + LC40® strain, experienced a significant 46% reduction in the incidence rate of gastrointestinal infections compared with the control group. Similarly, in the LC40® group, a significant reduction of 27% in the incidence rate of upper respiratory tract infections was observed when compared to the control group.

The bacterial counts analysed in the fecal samples from the infants showed that both lactobacilli and bifidobacteria were significantly higher in those ingesting the LC40® strain compared with controls at the end of the study.

Read study

 

Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1–6 months of age: A Randomised Controlled Trial
Results from this randomised clinical study on 121 healthy exclusively formula infants fed from 1 to 6 months old , showed that the formula supplemented with GOS + LC40® strain was associated with a 71% reduction in the incidence rate of gastrointestinal infections compared to the infants taking standard formula.

Additionally, the safety and tolerability of LC40® strain were evaluated and confirmed in this study.

Read Study

 

Long-term safety of early consumption of Lactobacillus fermentum CECT5716: A 3 year follow-up of a randomised, controlled trial.
Results from this 3-year follow-up study substantiate the long-term safety and tolerability profile of LC40® strain and complement the short-term safety data in infants that previously completed a 5-months RCT (from 1 to 6 months of age). The data collected showed that there were no detectable differences in anthropometric measurements between infants in the probiotic and control groups. In addition, no adverse effects related to the consumption of probiotic formula were recorded.

Read Study

 

Evaluation of the safety, tolerance, and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomised controlled trial
A randomised, doble-blind clinical study was performed in 126 healthy exclusively formula-fed infants, from 1 to 12 months old. Infants consuming the formula supplemented with LC40® showed a significant 44% reduction in the incidence of gastrointestinal infections compared to placebo. Additionally, those consuming LC40® experienced a significant shorter duration of diarrhea, 2.5 days less than the placebo.

Read study

 

Evaluation of the Effect of Limosilactobacillus fermentum CECT5716 on Gastrointestinal Infections in Infants: A Systematic Review and Meta-Analysis
Results from this meta-analysis, the highest level of scientific evidence, which included 435 healthy infants, showed a significant 48% reduction in the incidence rate of gastrointestinal infections for those receiving LC40® compared to placebo.

Read study

 

Beneficial Effects of Limosilactobacillus fermentum CECT 5716 Administration to Infants Delivered by Cesarean Section
The effects observed in the three RCT were specifically analyzed for those infants delivered by caesarean section, population at higher risk for infections.

Pooled results from the 173 infants born by C-section showed a significant reduction of 73% in the incidence of gastrointestinal infections in those receiving LC40® in comparison to the ones receiving the control formula.

Read study

LET’S DRIVE IMPACT TOGETHER

We are here to be your most valued partner – to pioneer, problem-solve and bring better nutrition to billions. Through the ingenuity of our people, our groundbreaking technologies can influence real change in the world.

Not just for you, our customer – but for all people, society and the planet.

Get in touch

Contact us today to explore collaboration opportunities or to learn more about our solutions.

This website is intended to provide business-to-business information. The information and statements herein are for example only and products and claims may not be approved in your region. The information and statements herein must be reviewed for compliance with applicable local laws. Please check with your local account representative to inquire about market clearance and claims approved for your region.

Nothing in this web site is intended to be an offer which is capable of acceptance and/or inducement of any kind. Descriptions of, or references or access to other publications within the web site do not imply endorsement of those publications. This web site could contain technical inaccuracies, and changes to the information contained herein may be made at any time without notice.

Kerry Group P.L.C. (including its associate and subsidiary companies) neither makes nor gives any warranty of any kind with respect to any subject matter or information included in, or for the completeness or accuracy, of this web site. Kerry Group P.L.C. is not responsible for any actions (or lack thereof) taken as a result of relying on or in any way using information contained in this website and in no event shall it be liable for any damages resulting from reliance on or use for any purpose of this information. Without limiting the above, Kerry Group P.L.C. shall have no responsibility for any act or omission of any other contributor.